Arcadia Biosciences (RKDA) 10-Q 10 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		24,642,960
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	202 Cousteau Place
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Davis
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95618
City Area Code	530
Local Phone Number	756-7077
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 22,719	$ 28,685
Accounts and other receivable, net of allowance for doubtful accounts of $13 and $76 as of September 30, 2022 and December 31, 2021, respectively	2,726	1,370
Inventories, net — current	3,342	4,433
Assets held for sale	254	0
Prepaid expenses and other current assets	990	900
Total current assets	30,031	35,388
Property and equipment, net	848	2,291
Right of use asset	2,073	3,081
Inventories, net — noncurrent	984	2,494
Intangible assets, net	373	484
Other noncurrent assets	165	180
Total assets	34,474	43,918
Current liabilities:
Accounts payable and accrued expenses	2,748	3,638
Amounts due to related parties	47	64
Operating lease liability — current	986	1,074
Other current liabilities	270	264
Total current liabilities	4,051	5,040
Operating lease liability — noncurrent	1,269	2,220
Common stock warrant and option liabilities	2,135	3,392
Other noncurrent liabilities	2,000	2,070
Total liabilities	9,455	12,722
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.001 par value -150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 24,642,960 and 22,184,235 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	65	63
Additional paid-in capital	278,618	257,515
Accumulated deficit	(253,615)	(226,485)
Total stockholders' equity	25,068	31,093
Non-controlling interest	(49)	103
Total stockholders' equity	25,019	31,196
Total liabilities and stockholders’ equity	$ 34,474	$ 43,918

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 13	$ 76
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	24,642,960	22,184,235
Common stock, outstanding	24,642,960	22,184,235

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenues	$ 1,878,000	$ 2,376,000	$ 8,956,000	$ 4,609,000
Operating expenses (income):
Cost of revenues	1,344,000	2,511,000	8,250,000	4,954,000
Research and development	255,000	1,038,000	1,009,000	3,328,000
Gain on sale of Verdeca	0	0	(1,138,000)	0
Impairment of intangible asset	0	120,000	72,000	120,000
Change in fair value of contingent consideration	0	0	(70,000)	(140,000)
Impairment of property and equipment	24,000	1,108,000	370,000	1,319,000
(Gain) loss on sale of property and equipment	0	0	(386,000)	17,000
Selling, general and administrative	4,835,000	6,312,000	13,834,000	16,733,000
Total operating expenses	6,458,000	11,089,000	21,941,000	26,331,000
Loss from operations	(4,580,000)	(8,713,000)	(12,985,000)	(21,722,000)
Interest income (expense)	95,000	(15,000)	123,000	(23,000)
Other income (expense), net	43,000	(7,000)	13,000	10,214,000
Change in fair value of common stock warrant and option liabilities	1,880,000	4,777,000	1,880,000	4,601,000
Gain on extinguishment of PPP loan	0	1,123,000	0	1,123,000
Issuance and offering costs	(314,000)	0	(314,000)	(769,000)
Net loss before income taxes	(2,876,000)	(2,835,000)	(11,283,000)	(6,576,000)
Income tax provision	(1,000)	(1,000)	(1,000)	(1,000)
Net loss	(2,877,000)	(2,836,000)	(11,284,000)	(6,577,000)
Net loss attributable to non-controlling interest	(10,000)	(661,000)	(152,000)	(1,199,000)
Net loss attributable to common stockholders	$ (2,867,000)	$ (2,175,000)	$ (11,132,000)	$ (5,378,000)
Net loss per share attributable to common stockholders:
Basic net loss per share attributable to common stockholders:	$ (0.12)	$ (0.10)	$ (0.48)	$ (0.26)
Diluted net loss per share attributable to common stockholders:	$ (0.12)	$ (0.10)	$ (0.48)	$ (0.26)
Denominator:
Weighted average number of common shares outstanding	24,552,543	22,177,423	22,984,816	20,976,105
Weighted average number of common shares outstanding - diluted	24,552,543	22,177,423	22,984,816	20,976,105
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustment	$ 0	$ (12,000)	$ 0	$ (24,000)
Other Comprehensive loss	0	(12,000)	0	(24,000)
Comprehensive loss attributable to common stockholders	(2,867,000)	(2,187,000)	(11,132,000)	(5,402,000)
Product
Revenues:
Total revenues	1,851,000	2,324,000	7,967,000	4,506,000
Royalty
Revenues:
Total revenues	17,000	35,000	117,000	86,000
License
Revenues:
Total revenues	$ 10,000	$ 17,000	$ 872,000	$ 17,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Arcadia Wellness [Member]	August 2022 Offering [Member]	January 2021 PIPE [Member]	Common Stock [Member]	Common Stock [Member] Arcadia Wellness [Member]	Common Stock [Member] August 2022 Offering [Member]	Common Stock [Member] January 2021 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Arcadia Wellness [Member]	Additional Paid-In Capital [Member] August 2022 Offering [Member]	Additional Paid-In Capital [Member] January 2021 PIPE [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Non-Controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2020	$ 28,552				$ 54				$ 239,496				$ (211,825)		$ 827
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2020					13,450,861
Issuance of shares				$ 15,516				$ 8				$ 15,508
Issuance of shares, Shares								7,876,784
Offering costs				(2,084)								(2,084)
Issuance of placement agent warrants				$ 942								$ 942
Issuance of shares related to employee stock purchase plan	21								21
Issuance of shares related to employee stock purchase plan, Shares					8,604
Stock-based compensation	325								325
Non-controlling interest contributions	750														750
Net income (loss)	1,681												2,058		(377)
Stockholders Equity, Ending Balance at Mar. 31, 2021	45,703				$ 62				254,208				(209,767)		1,200
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2021					21,336,249
Stockholders Equity, Beginning Balance at Dec. 31, 2020	28,552				$ 54				239,496				(211,825)		827
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2020					13,450,861
Foreign currency translation adjustment	(24)
Net income (loss)	(6,577)
Stockholders Equity, Ending Balance at Sep. 30, 2021	40,223				$ 63				257,009				(217,203)	$ (24)	378
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2021					22,184,235
Stockholders Equity, Beginning Balance at Dec. 31, 2020	28,552				$ 54				239,496				(211,825)		827
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2020					13,450,861
Net income (loss)	(16,100)
Stockholders Equity, Ending Balance at Dec. 31, 2021	31,196				$ 63				257,515				(226,485)		103
Stockholders Equity, Ending Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021	3,392								19,390				(15,998)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2021					22,184,235
Stockholders Equity, Beginning Balance at Mar. 31, 2021	45,703				$ 62				254,208				(209,767)		1,200
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2021					21,336,249
Issuance of common stock at closing of acquisition transaction		$ 2,053				$ 1				$ 2,052
Issuance of common stock at closing of acquisition transaction, Shares						827,401
Foreign currency translation adjustment	(12)													(12)
Stock-based compensation	356								356
Net income (loss)	(5,422)												(5,261)		(161)
Stockholders Equity, Ending Balance at Jun. 30, 2021	42,678				$ 63				256,616				(215,028)	(12)	1,039
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2021					22,163,650
Issuance of shares related to employee stock purchase plan	17								17
Issuance of shares related to employee stock purchase plan, Shares					6,585
Foreign currency translation adjustment	(12)													(12)
Stock-based compensation	354								354
Issuance of shares related to exercise of Service and Performance Warrants	22								22
Issuance of shares related to exercise of Service and Performance Warrants, Shares					14,000
Net income (loss)	(2,836)												(2,175)		(661)
Stockholders Equity, Ending Balance at Sep. 30, 2021	40,223				$ 63				257,009				(217,203)	$ (24)	378
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2021					22,184,235
Stockholders Equity, Beginning Balance at Dec. 31, 2021	$ 31,196				$ 63				257,515				(226,485)		103
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2021					22,184,235
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Issuance of shares related to employee stock purchase plan	$ 4								4
Issuance of shares related to employee stock purchase plan, Shares					4,683
Stock-based compensation	260								260
Net income (loss)	(4,610)												(4,488)		(122)
Stockholders Equity, Ending Balance at Mar. 31, 2022	30,242				$ 63				277,169				(246,971)		(19)
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2022					22,188,918
Stockholders Equity, Beginning Balance at Dec. 31, 2021	31,196				$ 63				257,515				(226,485)		103
Stockholders Equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021	3,392								19,390				(15,998)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2021					22,184,235
Foreign currency translation adjustment	0
Net income (loss)	(11,284)
Stockholders Equity, Ending Balance at Sep. 30, 2022	25,019				$ 65				278,618				(253,615)		(49)
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2022					24,642,960
Stockholders Equity, Beginning Balance at Mar. 31, 2022	30,242				$ 63				277,169				(246,971)		(19)
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2022					22,188,918
Stock-based compensation	323								323
Net income (loss)	(3,797)												(3,777)		(20)
Stockholders Equity, Ending Balance at Jun. 30, 2022	26,768				$ 63				277,492				(250,748)		(39)
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2022					22,188,918
Issuance of shares			$ 1,176				$ 2				$ 1,174
Issuance of shares, Shares							2,450,000
Offering costs			$ (365)								$ (365)
Issuance of shares related to employee stock purchase plan	3								3
Issuance of shares related to employee stock purchase plan, Shares					4,042
Foreign currency translation adjustment	0
Stock-based compensation	314								314
Net income (loss)	(2,877)												(2,867)		(10)
Stockholders Equity, Ending Balance at Sep. 30, 2022	$ 25,019				$ 65				$ 278,618				$ (253,615)		$ (49)
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2022					24,642,960

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,877,000)	$ (4,610,000)	$ (2,836,000)	$ 1,681,000	$ (11,284,000)	$ (6,577,000)	$ (16,100,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant and option liabilities	(1,880,000)		(4,777,000)		(1,880,000)	(4,601,000)
Change in fair value of contingent consideration	0		0		(70,000)	(140,000)
Issuance and offering costs	314,000		0		314,000	769,000
Depreciation					354,000	737,000
Amortization of intangible assets					39,000	99,000
Lease amortization					686,000	914,000
Impairment of intangible assets	0		120,000		72,000	120,000	3,300,000
(Gain) loss on disposal of property and equipment	0		0		(386,000)	17,000
Stock-based compensation	314,000		354,000		897,000	1,035,000
Bad debt expense					32,000	0
Realized gain on corporate securities					0	(10,222,000)
Impairment of property and equipment					370,000	1,319,000
Write-down of inventory	15,000		818,000		1,530,000	1,802,000
Gain on extinguishment of PPP loan	0		(1,123,000)		0	(1,123,000)
Gain on sale of Verdeca	0		0		(1,138,000)	0
Changes in operating assets and liabilities:
Accounts receivable					(534,000)	(47,000)
Inventories					1,071,000	(2,651,000)
Prepaid expenses and other current assets					(90,000)	(452,000)
Other noncurrent assets					15,000	(159,000)
Accounts payable and accrued expenses					(890,000)	972,000
Amounts due to related parties					(17,000)	(29,000)
Unearned revenue					0	(8,000)
Other current liabilities					6,000	1,000
Operating lease liabilities					(718,000)	(984,000)
Net cash used in operating activities					(11,621,000)	(19,208,000)	(25,900,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	5,000				897,000	2,000
Proceeds from sale of Verdeca - earn-out received					285,000
Purchases of property and equipment					(46,000)	(919,000)
Acquisitions, net of cash acquired					0	(4,250,000)
Proceeds from sales and maturities of investments					0	21,845,000
Net cash provided by (used in) investing activities					1,136,000	16,678,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of warrants					0	22,000
Principal payments on debt						(2,032,000)
Proceeds from ESPP purchases					7,000	39,000
Capital contributions received from non-controlling interest					0	750,000
Net cash provided by financing activities					4,519,000	22,014,000
Effects of foreign currency translation on cash and cash equivalents					0	(1,000)
Net (decrease) increase in cash and cash equivalents					(5,966,000)	19,483,000
Cash and cash equivalents - beginning of period		$ 28,685,000		$ 16,043,000	28,685,000	16,043,000	16,043,000
Cash and cash equivalents - end of period	$ 22,719,000		$ 35,526,000		22,719,000	35,526,000	$ 28,685,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes						1,000
Cash paid for interest					1,000	25,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Shares of common stock issued at closing of Arcadia Wellness transaction					0	2,053,000
Right of use assets obtained in exchange for new operating lease liabilities					114,000	1,662,000
Proceeds from sale of Verdeca in accounts and other receivable					854,000	0
August 2022 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock pre-funded warrants and preferred investment options					5,000,000	0
Payments of offering costs					(488,000)	0
January 2021 PIPE Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from offering					0	25,147,000
Payments of offering costs					0	(1,912,000)
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs related to purchase agreement					0	942,000
August 2022 RDO Securities Purchase Agreement [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock options issued to placement agent and included in offering costs					191,000	0
Accounting Standards Update 2020-06 [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrant liabilities reclassified to equity					$ 3,392,000	$ 0

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional office space in Dallas, TX, and additional facilities in American Falls, Idaho. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based health and wellness products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients and health and wellness products, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The acquisition of the businesses of Lief Holdings, LLC (“Lief”), EKO Holdings, LLC (“Eko”) and Live Zola, LLC (“Zola”) added bath and body care products, as well as coconut water, to the Company’s portfolio. In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 6), acquired the businesses of Eko, Lief, and Zola. The acquisition included consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of natural body care products and ProVault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. On July 8, 2022, the Company entered into an agreement to license Saavy Naturals™ to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). See Note 6 for a discussion of the licensing agreement. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 8) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $ 10.0 million on sales of Haab 4 soybeans (“HB4”) soybean. An additional $ 2.0 million in cash is to be paid upon achievement by Verdeca of reaching commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for “food and feed”. During the second quarter of 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $ 862,000 and a gain on sale of Verdeca of $ 1.1 million on the condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022, the Company received payment of $ 500,000 with the remaining $ 1.5 million in accounts receivable and other receivables, which the Company anticipates to receive over the next six months pursuant to the agreement. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 10,000 and $ 152,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2022, respectively. Net loss attributable to non-controlling interest for the three and nine months ended September 30, 2021 was $ 661,000 and $ 1.2 million, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2022. Liquidity, Capital Resources, and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of September 30, 2022, the Company had an accumulated deficit of $ 253.6 million, and cash and cash equivalents of $ 22.7 million . For the nine months ended September 30, 2022, the Company had a net loss of $ 11.3 million and net cash used in operations of $ 11.6 million. For the twelve months ended December 31, 2021, the Company had net losses of $ 16.1 million and net cash used in operations of $ 25.9 million. With cash and cash equivalents of $ 22.7 million as of September 30, 2022, the Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . Additionally, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 in April 2019 and ASU 2019-05, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief in May 2019. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. In November 2019, the FASB issued ASU No. 2019-10, which defers the effective date of ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on the condensed consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40) . The FASB Board is issuing this Update to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. In addressing the complexity, the FASB Board focused on amending the guidance on convertible instruments and the guidance on the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The amendments in this Update are effective for public business entities that meet the definition of a smaller reporting company, as defined by the SEC, for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU No. 2020-06 on January 1, 2022 , using the modified retrospective method. Prior to the adoption of ASU No. 2020-06, the Company had liability classified awards due to the existence of certain contingent cash payment feature. Upon adoption, these clauses no longer preclude equity classification. Under the modified retrospective method, the historical mark-to-market adjustments related to outstanding awards were reversed through retained earnings and the original carrying value of the awards were reclassified to additional paid-in capital. Adoption of the new standard resulted in an increase to accumulated deficit of $ 16.0 million, an increase to additional paid-in capital of $ 19.4 million, and a decrease to common stock warrant liabilities of $ 3.4 million, on the condensed consolidated balance sheets. In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options . The amendments in this Update clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this Update affect all entities that issue freestanding written call options that are classified in equity. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted ASU No. 2021-04 on January 1, 2022 with an immaterial impact on the Company’s disclosures.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory	3. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of revenues and are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded write-downs of CBD oil of $ 15,000 during the three months ended September 30, 2022 and of wheat, hemp seed, CBD oil and body care inventories of $ 1.5 million during the nine months ended September 30, 2022. Of inventories write-downs during the nine months ended September 30, 2022 , $ 394,000 is related to the Radiance Beauty licensing agreement discussed in Note 6. The Company recorded write-downs of wheat and hemp seed inventories of $ 818,000 and $ 1.8 million during the three and nine months ended September 30, 2021, respectively. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Company’s expenses in the period the write down is taken and materially affect the Company’s operating results. Inventories, net consist of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 1,119 $ 1,851 Goods in process 92 842 Finished goods 3,115 4,234 Inventories $ 4,326 $ 6,927

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, 2022 December 31, 2021 Laboratory equipment $ 1,688 $ 2,659 Software and computer equipment 559 548 Machinery and equipment 653 1,809 Furniture and fixtures 108 211 Vehicles 333 417 Leasehold improvements 2,203 2,306 Property and equipment, gross 5,544 7,950 Less: accumulated depreciation and amortization ( 4,696 ) ( 5,659 ) Property and equipment, net $ 848 $ 2,291 Depreciation expense was $ 354,000 and $ 737,000 for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, and December 31, 2021, respectively, there was $ 10,000 and $ 267,000 of construction in progress included in property and equipment that had not been placed into service and was not subject to depreciation. Property and equipment are considered assets held for sale when management approves and commits to a plan to dispose of a property or group of properties. The property and equipment held for sale prior to the sale date is separately presented, within current assets, on the condensed consolidated balance sheet as assets held for sale. During the three and nine months ended September 30, 2022, management initiated the sale of property and equipment related to the Davis laboratory and Archipelago. The Company completed the sale of such property and equipment with a gain on sale of property and equipment in the amount of $ 0 and $ 386,000 recorded on the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2022, respectively. The proceeds related to the sale of property and equipment during the three and nine months ended September 30, 2022 are $ 5,000 and $ 897,000 , respectively. The Company had no sales of assets held for sale during the three and nine months ended September 30, 2021. Property and equipment related to Archipelago, in the amount of $ 254,000 , have been classified as assets held for sale, and are recorded at fair value as of September 30, 2022. The fair value has been estimated using publicly available prices for some of the assets, and business partners' estimates for assets with prices not readily available, due to the relatively small size of the industry in which they can be used. During the three and nine months ended September 30, 2022, the Company recorded write-downs of property and equipment of $ 24,000 and $ 370,000 , respectively. During the nine months ended September 30, 2022 , write-downs of $ 320,000 were related to the Radiance Beauty licensing agreement. See Note 6 for further discussion of the licensing agreement. During the three and nine months ended September 30, 2021 , the Company recorded a write-down of property and equipment related to Archipelago in the amount of $ 1.1 million and $ 1.3 million, respectively.

Investments and Fair Value Inst

Investments and Fair Value Instruments	9 Months Ended
	Sep. 30, 2022
Investments And Fair Value Instruments [Abstract]
Investments and Fair Value Instruments	5. Investments and Fair Value Instruments Investments The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized and realized gains and losses are recognized as other income in the condensed consolidated statements of operations and comprehensive loss. The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2022 and December 31, 2021. (Dollars in thousands) Amortized Unrealized Unrealized Estimated September 30, 2022 Cash equivalents: Money market funds $ 20,477 $ — $ — $ 20,477 Total Assets at Fair Value $ 20,477 $ — $ — $ 20,477 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2021 Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842 The Company did no t have any investment categories that were in a continuous unrealized loss position for more than twelve months as of September 30, 2022. Fair Value Measurement The fair value of the investment securities at September 30, 2022 were as follows: Fair Value Measurements at September 30, 2022 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 20,477 $ — $ — $ 20,477 Total Assets at Fair Value $ 20,477 $ — $ — $ 20,477 The fair value of the investment securities at December 31, 2021 were as follows: Fair Value Measurements at December 31, 2021 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2022 or 2021. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable and other receivables, accounts payable, accrued liabilities, and notes payable. For accounts receivable and other receivables, accounts payable, accrued liabilities, and notes payable the carrying amounts of these financial instruments as of September 30, 2022 and December 31, 2021 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah, Inc. ("Anawah") acquisition as described in Note 15, as well as preferred investment options related to the August 2022 Registered Direct Offering described in Note 11. As of December 31, 2021, the Company also had common stock warrant liabilities related to the March 2018, the June 2019, the September 2019, and the January 2021 Offerings, described in Note 11, which were reclassified to additional paid-in capital upon adoption of ASU 2020-06, as of January 1, 2022. See Note 2 for details of the adoption of ASU 2020-06. The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of September 30, 2022 and December 31, 2021, using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Company’s ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement. The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at September 30, 2022: August 2022 Options August 2022 Placement Agent Options Remaining term (in years) 4.92 4.92 Expected volatility 128.5 % 128.5 % Risk-free interest rate 4.1 % 4.1 % Expected dividend yield 0 % 0 % The significant input used in the fair value measurement of the Company’s Level 3 options liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement. The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) Common Stock Common Common Common August 2022 August 2022 Contingent Total Balance as of December 31, 2021 $ 7 $ 170 $ 223 $ 2,993 $ — $ — $ 2,070 $ 5,463 Reclassification upon adoption ( 7 ) ( 170 ) ( 223 ) ( 2,993 ) — — — ( 3,392 ) Initial recognition — — — — 3,824 191 — 4,015 Change in fair value and other adjustments — — — — ( 1,791 ) ( 89 ) ( 70 ) ( 1,950 ) Balance as of September 30, 2022 $ — $ — $ — $ — $ 2,033 $ 102 $ 2,000 $ 4,135 The Company recorded aggregate impairment charges of $ 442,000 and $ 1.4 million during the nine months ended September 30, 2022 and 2021, respectively, related to intangible assets and other long-lived assets. The Company has classified the fair value measurements as a Level 3 measurement in the fair value hierarchy because they involve significant unobservable inputs such as cash flow projections, discount rates and management assumptions. . The Company has classified the fair value measurements as a Level 3 measurement in the fair value hierarchy as the fair value has been estimated using publicly available prices for some of the assets, and business partners' estimates for assets with prices not readily available, due to the relatively small size of the industry in which they can be used.

Arcadia Wellness Acquisition

Arcadia Wellness Acquisition	9 Months Ended
	Sep. 30, 2022
Arcadia Wellness Acquisition [Member]
Business Acquisition [Line Items]
Arcadia Wellness Acquisition	6. Arcadia Wellness Acquisition On May 17, 2021, the Company’s wholly owned subsidiary Arcadia Wellness, acquired the assets of Eko, Lief, and Zola. The acquisition included consumer brands of bath and body care products such as Soul Spring, the CBD-infused botanical therapy brand, Saavy Naturals, a line of natural body care products and ProVault, a CBD-infused sports performance formula. Also included in the purchase was Zola, a coconut water sourced from Thailand. The acquisition was recorded as a business combination, in accordance with ASC 805. The purchase price consideration for the acquisition totaled an estimated $ 6.1 million, of which $ 4.0 million in cash and $ 2.1 million in the form of 827,401 shares of the Company’s common stock, was paid during the month of May 2021. The cash consideration paid for the acquisition was funded by cash on hand. Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the Arcadia Wellness acquisition of approximately $ 850,000 included in selling, general and administrative expenses in the Company's consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021. The Company performed an allocation of purchase price as of the acquisition date based on management's estimates of fair value. The Company believes its estimates and assumptions are reasonable. The following table presents the allocation of the purchase price of the assets acquired at fair value at the acquisition date: Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052 The former shareholders of Eko, Lief, and Zola remain responsible for their pre-acquisition liabilities. In connection with the acquisition, the Company entered into a lease agreement for the use of offices, production equipment acquired, and storage warehouses. The lease was effective on May 17, 2021 and has a term of 3 years . For the period from January 1, 2022 to September 30, 2022 , the Company recognized approximately $ 5.6 million of revenue and $ 1.3 million of net loss relating to Arcadia Wellness, which included charges related to the Radiance Beauty licensing agreement discussed below, as well as the amortization of acquired intangible assets. For the period from May 17, 2021 to December 31, 2021, the Company recognized approximately $ 4.3 million of revenue and $ 7.5 million of net loss relating to Arcadia Wellness, which included charges for the amortization of acquired intangible assets. Acquired intangible assets of $ 3.5 million include trade names and trademarks of $ 2.9 million (indefinite useful life), customer list of $ 360,000 ( fifteen-year useful life) and formulations of $ 260,000 ( ten-year useful life). For impairments related to the acquired intangible assets see Note 7. The total weighted average amortization period for the acquired intangibles is 12.9 years. The acquisition produced $ 1.2 million of goodwill, which was fully impaired during the year ended December 31, 2021, due to weakness in some of the newly acquired consumer product margins, combined with a volatile economic climate and higher than normal inflation. Goodwill arising from the Arcadia Wellness acquisition was not deductible for tax purposes. On July 8, 2022, the Company entered into a licensing agreement with Radiance Beauty. Under the terms of the licensing agreement, Radiance Beauty was granted an exclusive, transferable, sublicensable, perpetual, worldwide license to use the Saavy Naturals™ mark and to modify, manufacture, distribute, market and sell related products. In addition, as part of the licensing agreement, Radiance Beauty received the remaining accounts receivables and inventory balances after July 31, 2022, certain equipment, as well as three months of salaries in the amount of $ 355,000 and rent, maintenance and utilities in the amount of $ 19,000 . Radiance Beauty is subleasing space from the Company and will pay the Company a 4 % royalty of gross sales of products beginning January 1, 2023. During the nine months ended September 30, 2022 , accounts receivables and inventories of $ 21,000 and $ 394,000 , respectively, were written down. In addition, property and equipment and intangible assets were written down by $ 320,000 and $ 72,000 , respectively, during the nine months ended September 30, 2022. Supplemental Pro-Forma Results of Operations (Unaudited) The following unaudited pro-forma condensed consolidated results of operations for the three and nine months ended September 30, 2022 and 2021, have been prepared as if the acquisition of Arcadia Wellness had occurred on January 1, 2021 and includes adjustments for amortization of intangibles, and the addition to basic and diluted weighted average number of shares outstanding. For the Three Months For the Nine Months 2022 2021 2022 2021 Total revenues $ 1,878 $ 2,376 $ 8,956 $ 6,892 Net loss ( 2,877 ) ( 2,836 ) ( 11,284 ) ( 8,296 ) Net loss attributable to common stockholders $ ( 2,867 ) $ ( 2,175 ) $ ( 11,132 ) $ ( 7,109 ) Weighted average shares - Basic and diluted 24,552,543 22,175,423 22,984,816 21,286,380 Net loss per share attributable to common stockholders: Basic and diluted $ ( 0.12 ) $ ( 0.10 ) $ ( 0.48 ) $ ( 0.33 )

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	7. Intangible assets, net The Company’s intangible assets, net, consist of the following: September 30, 2022 December 31, 2021 Gross Accumulated Amortization Net Carrying Gross Accumulated Amortization Net Carrying Amortized intangible assets Intellectual property $ 254 $ 141 $ 113 $ 258 $ 107 $ 151 Customer lists 64 32 32 71 26 45 Total amortizable intangible assets $ 318 $ 173 $ 145 $ 329 $ 133 $ 196 Indefinite-lived intangible assets Brands and trademarks $ 228 $ — $ 228 $ 288 $ — $ 288 Total intangible asset, net $ 546 $ 173 $ 373 $ 617 $ 133 $ 484 (1) The gross carrying amounts included in this table reflect the effects of the impairments of intangible assets recorded during the year ended December 31, 2021, when the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of the acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $ 3.3 million in the condensed consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. (2) The Company recorded an impairment of intangible assets in the amount of $ 72,000 during the nine months ended September 30, 2022 related to the Radiance Beauty licensing agreement. Intellectual property and customer lists will be amortized based on their useful lives ranging between 4 and 15 years . As of September 30, 2022, future amortization of intellectual property and customer lists is as follows: Year Ending December 31, 2022 (excluding the nine months ended September 30, 2022) $ 13 2023 53 2024 53 2025 4 2026 4 Thereafter 18 Total $ 145

Consolidated Joint Venture

Consolidated Joint Venture	9 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Consolidated Joint Venture	8. Consolidated Joint Venture In 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago . As of September 30, 2022, the Company and Legacy hold 50.75 % and 49.25 % interests in Archipelago, respectively, and have made capital contributions to Archipelago of $ 3.1 million and $ 3.0 million, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $ 10,000 and $ 152,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2022 , respectively. Net loss attributable to non-controlling interest of $ 661,000 and $ 1.2 million was recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2021, respectively. Legacy’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. Refer to Note 1 for basis of presentation. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.

Collaborative Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangements	9. Collaborative Arrangements In August 2017 , the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva AgriScience (“Corteva”) and involves a joint operating activity where both Arcadia and Corteva are active participants in the activities of the collaboration. Arcadia and Corteva participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development , which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Lessee Disclosure [Abstract]
Leases	10. Leases Operating Leases As of September 30, 2022, the Company leases office space in Davis, CA, and Dallas, TX, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases a portion of the Davis office lease to third parties. In May 2022, the Company terminated its lease for office space in Chesterfield, MO effective September 30, 2022. The original lease term was scheduled to expire in May 2024 . As a result, the Company paid $ 47,000 in early termination fees during the nine months ended September 30, 2022. In addition, the Company subleased the facility in Chatsworth, CA to Radiance Beauty as part of the licensing agreement beginning November 1, 2022 for the remainder of the lease term. During the nine months ended September 30, 2022, the Company entered into an agreement to lease office space in Dallas, TX. The new lease commenced in July 2022. Some leases (the Davis and Dallas offices, a warehouse, and a copy machine) include one or more options to renew , with renewal terms that can extend the lease term from one to six years . The exercise of lease renewal options is at the Company’s sole discretion. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification September 30, 2022 December 31, 2021 Assets Operating lease assets Right of use asset $ 2,073 $ 3,081 Total leased assets $ 2,073 $ 3,081 Liabilities Current - Operating Operating lease liability- current $ 986 $ 1,074 Noncurrent - Operating Operating lease liability- noncurrent 1,269 2,220 Total leased liabilities $ 2,255 $ 3,294 Lease Cost Classification Three Three Nine Nine Operating lease cost SG&A and R&D Expenses $ 271 $ 319 $ 815 $ 955 Short term lease cost (1) R&D Expenses ( 7 ) 37 4 67 Short term lease cost SG&A Expenses — 14 0 29 Sublease income (2) SG&A and R&D Expenses ( 99 ) ( 10 ) ( 276 ) ( 43 ) Net lease cost $ 165 $ 360 $ 543 $ 1,008 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term September 30, 2022 December 31, 2021 Weighted-average remaining 2.3 2.7 Weighted-average discount rate 6.4 % 6.0 %

Equity Financing

Equity Financing	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Equity Financing	11. Equity Financing Private Placements In January 2021, the Company issued in a private placement offering (the “January 2021 Private Placement”) pursuant to a securities purchase agreement (“January 2021 Purchase Agreement”) (i) 7,876,784 shares of its common stock, and (ii) warrants to purchase up to 3,938,392 shares of common stock at an exercise price of $ 3.13 per share (the “January 2021 Warrants”) and raised total gross proceeds of $ 25.1 million. The January 2021 Warrants are exercisable at any time at the option of the holder and expire 5.5 years from the date of issuance. In connection with the January 2021 Private Placement, the Company granted to a placement agent warrants to purchase a total of 393,839 shares of Common Stock (the “January 2021 Placement Agent Warrants”) that have an exercise price per share equal to $ 3.99 and a term of 5.5 years from the date of issuance. The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature. The Company utilized a Black Scholes Merton model on January 28, 2021 with the following assumptions: volatility of 123.8 %, stock price of $ 2.88 and risk-free rate of 0.5 %. The estimated fair value of the common stock warrant liability was subsequently remeasured at December 31, 2021 with the changes recorded on the Company’s consolidated statements of operations and comprehensive loss. The January 2021 Placement Agent Warrants were issued for services performed by the placement agent as part of the January 2021 Private Placement and were treated as offering costs. The value of the January 2021 Placement Agent Warrants was determined to be $ 942,000 , calculated using a Black-Scholes Model. The Company incurred additional offering costs totaling $ 1.9 million that consist of direct incremental legal, advisory, accounting and filing fees relating to the January 2021 Private Placement. The offering costs, inclusive of the January 2021 Placement Agent Warrants, totaled $ 2.8 million and allocated to the common stock warrant liability and the common stock using their relative fair values. A total of $ 769,000 was allocated to the common stock warrant liability and expensed and the remaining $ 2.0 million was allocated to the common stock and offset to additional paid in capital. In March 2018, the Company issued in a private placement offering (the “March 2018 Private Placement”) pursuant to a securities purchase agreement (“March 2018 Purchase Agreement”) (i) 300,752 shares of its common stock and (ii) warrants to purchase up to 300,752 shares of common stock at an initial exercise price equal to $ 45.75 (the “March 2018 Warrants”) and raised total gross proceeds of $ 10.0 million. The March 2018 Warrants are exercisable at any time at the option of the holder and expire five years from the date of issuance. In connection with the March 2018 Private Placement, the Company granted to a placement agent warrants to purchase a total of 15,038 shares of Common Stock (the “March 2018 Placement Agent Warrants”) that have an exercise price per share equal to $ 41.5625 and a term of five years from the date of issuance. The number of shares of common stock and the number and exercise price of the March 2018 Warrants issued in the March 2018 Private Placement were subject to adjustments as provided in the March 2018 Purchase Agreement. Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the purchasers was 1,201,634 , the total number of shares issuable upon exercise of the March 2018 Warrants was 1,282,832 and the per share exercise price of the March 2018 Warrants was $ 10.7258 . Registered Direct Offerings On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018 (“2018 Shelf Registration Statement”). On April 21, 2022, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on May 12, 2022 (“2022 Shelf Registration Statement”). Each of the 2018 Shelf Registration Statement and the 2022 Shelf Registration Statement allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having aggregate offering prices of up to $ 50.0 million. The Company ceased being able to use the 2018 Shelf Registration Statement after June 8, 2021, the three-year anniversary of its effective date. The 2022 Shelf Registration Statement may no longer be used after May 12, 2025, the three-year anniversary of its effective date. In August 2022, the Company entered into a securities purchase agreement (the “August 2022 Purchase Agreement”) pursuant to which it sold (i) 2,450,000 registered shares of its common stock, pursuant to the 2022 Shelf Registration Statement, (ii) pre-funded common stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to 2,272,506 shares of common stock, at an exercise price of $ 0.0001 per share, which Pre-Funded Warrants were registered under the 2022 Shelf Registration Statement, and (iii) unregistered preferred investment options (the "August 2022 Options") to purchase up to 4,722,506 shares of common stock, at an exercise price of $ 0.93376 per share, in a private placement, for total gross proceeds of $ 5.0 million (the “August 2022 Registered Direct Offering”). The August 2022 Registered Direct Offering closed on August 16, 2022 . The August 2022 Pre-Funded Warrants became exercisable upon issuance and are exercisable until exercised in full. The August 2022 Options became exercisable upon issuance and expire 5 years after the date of issuance. In connection with the August 2022 Registered Direct Offering, the Company granted to a placement agent preferred investment options ("August 2022 Placement Agent Options") to purchase a total of 236,125 shares of common stock that have an exercise price per share equal to $ 1.32 and a term of five years . The August 2022 Options and August 2022 Placement Agent Options are classified as liabilities within Level 3 due to a certain early settlement provisions that preclude them from equity classification. The Company utilized a Black-Scholes Merton model on August 16, 2022 with the following assumptions: volatility of 128.46 %, stock price of $ 0.94 , risk-free rate of 2.97 % and a term of 5 years . The estimated fair value of the common stock option liabilities was subsequently remeasured at September 30, 2022 with the changes recorded on the Company’s consolidated statements of operations and comprehensive loss. The August 2022 Placement Agent Options were issued for services performed by the placement agent as part of the August 2022 Registered Direct Offering and were treated as offering costs. The value of the August 2022 Placement Agent Options was determined to be $ 191,000 , calculated using a Black-Scholes Model. The Company incurred additional offering costs totaling $ 488,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the August 2022 Registered Direct Offering. The offering costs, inclusive of the August 2022 Placement Agent Options, totaled $ 679,000 and were allocated to the common stock option liabilities, the common stock and Pre-Funded Warrants using their relative fair values. A total of $ 314,000 was allocated to the common stock option liabilities and expensed while the remaining $ 365,000 was allocated to the common stock and Pre-Funded Warrants and offset to additional paid in capital. In December 2020, the Company entered into a securities purchase agreement (the “December 2020 Purchase Agreement”) pursuant to which it sold (i) 2,618,658 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 2,618,658 shares of its common stock (the “December 2020 Warrants”) in a private placement, for total gross proceeds of $ 8.0 million (the “December 2020 Registered Direct Offering”). The December 2020 Registered Direct Offering closed on December 22, 2020 . The December 2020 Warrants have an exercise price of $ 3.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the December 2020 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 130,933 shares of common stock (“December 2020 Placement Agent Warrants”) that have an exercise price per share equal to $ 3.8188 and a term of five years . In September 2019, the Company entered into a securities purchase agreement (the “September 2019 Purchase Agreement”) pursuant to which it sold (i) 1,318,828 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 659,414 shares of its common stock (the “September 2019 Warrants”) in a private placement, for total gross proceeds of $ 10.0 million (the “September 2019 Registered Direct Offering”). The September 2019 Registered Direct Offering closed on September 5, 2019 . The September 2019 Warrants have an exercise price of $ 7.52 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the September 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 65,942 shares of common stock (“September 2019 Placement Agent Warrants”) that have an exercise price per share equal to $ 9.4781 and a term of five years . In June 2019, the Company entered into a securities purchase agreement (the “June 2019 Purchase Agreement”) pursuant to which it sold (i) 1,489,575 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 1,489,575 shares of its common stock (the “June 2019 Warrants”) in a private placement, for total gross proceeds of $ 7.5 million (the “June 2019 Registered Direct Offering”). The June 2019 Registered Direct Offering closed on June 14, 2019 . The June 2019 Warrants have an exercise price of $ 5.00 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2019 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 74,479 shares of common stock (“June 2019 Placement Agent Warrants”) that have an exercise price per share equal to $ 6.2938 and a term of five years . In June 2018, the Company entered into a securities purchase agreement (the “June 2018 Purchase Agreement”) pursuant to which it sold (i) 1,392,345 registered shares of its common stock pursuant to the 2018 Shelf Registration Statement and (ii) unregistered warrants to purchase 1,392,345 shares of its common stock (the “June 2018 Warrants”) in a private placement, for total gross proceeds of $ 14.0 million (the “June 2018 Registered Direct Offering”). The June 2018 Registered Direct Offering closed on June 14, 2018 . The June 2018 Warrants have an exercise price of $ 9.94 per share, became exercisable upon issuance and expire 5.5 years after the date of issuance. In connection with the June 2018 Registered Direct Offering, the Company granted to a placement agent warrants to purchase a total of 69,617 shares of common stock (“June 2018 Placement Agent Warrants”) that have an exercise price per share equal to $ 12.568 and a term of five years .

Warrants and Options

Warrants and Options	9 Months Ended
	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants and Options	12. Warrants and Options Equity Classified Common Stock Warrants The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of September 30, 2022 or December 31, 2021, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at August 2022 Pre-Funded Warrants August 2022 perpetual $ 0.00 — — — 2,272,506 January 2021 Placement Agent Warrants January 2021 5.5 years $ 3.99 — 393,839 — 393,839 January 2021 Service and Performance Warrants (1) January 2021 2 years $ 3.08 — 7,500 — 7,500 December 2020 Warrants December 2020 5.5 years $ 3.00 — 2,618,658 — 2,618,658 December 2020 Placement Agent Warrants December 2020 5 years $ 3.82 — 130,933 — 130,933 July 2020 Warrants July 2020 5.5 years $ 3.85 — 641,416 — 641,416 July 2020 Placement Agent Warrants July 2020 5.5 years $ 4.97 — 32,071 — 32,071 May 2020 Warrants May 2020 5 years $ 4.78 — 1,392,345 — 1,392,345 May 2020 Placement Agent Warrants May 2020 5 years $ 6.13 — 69,617 — 69,617 March 2020 Service and Performance Warrants (1) March 2020 3 years $ 2.50 — 18,350 — 18,350 February 12, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 4.71 — 150,000 — — February 3, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 4.91 — 10,000 — — September 2019 Placement Agent Warrants September 2019 5 years $ 9.48 — 65,942 — 65,942 June 2019 Placement Agent Warrants June 2019 5 years $ 6.29 — 74,479 — 74,479 April 2019 Service and Performance Warrants (1) April 2019 5 years $ 6.18 — 145,154 — 145,154 June 2018 Placement Agent Warrants June 2018 5 years $ 12.57 — 69,617 — 69,617 March 2018 Placement Agent Warrants March 2018 5 years $ 41.56 — 15,038 — 15,038 January 2021 Warrants (2) January 2021 5.5 years $ 3.13 — 3,938,392 — 3,938,392 September 2019 Warrants (2) September 2019 5.5 years $ 7.52 — 659,414 — 659,414 June 2019 Warrants (2) June 2019 5.5 years $ 5.00 — 435,830 — 435,830 June 2018 Warrants (2) June 2018 5.5 years $ 9.94 — — — — March 2018 Warrants (2) March 2018 5 years $ 10.73 — 641,416 — 641,416 Total — 11,510,011 — 13,622,517 (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and were adjusted to fair value at each balance sheet date. Upon adoption of ASU No. 2020-06 on January 1, 2022, all of the common stock warrant liabilities have been reclassified to equity classified common stock warrants, due to the elimination of the contingent cash payments as criteria for liability classification. (3) These warrants expired in February 2022 . Liability Classified Preferred Investment Options The preferred investment options issued in connection with the August 2022 Registered Direct Offering contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows: Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at August 2022 Options August 2022 5 years $ 0.93 — — — 4,722,506 August 2022 Placement Agent Options August 2022 5 years $ 1.32 — — — 236,125 Total — — — 4,958,631

Stock-Based Compensation and Em

Stock-Based Compensation and Employee Stock Purchase Program	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation and Employee Stock Purchase Program	13. Stock-Based Compensation and Employee Stock Purchase Program Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, there might be alternative vesting schedules, as approved by the Board. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested. In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares. On May 17, 2021, upon completion of the Arcadia Wellness transaction, the Company granted 248,000 inducement stock option pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. On May 28, 2021, the Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of these inducement stock options. On February 2, 2022, Sta nley Jacot, Jr. was hired as the new president and chief executive officer of the Company. The Company granted Mr. Jacot an inducement stock option to purchase 316,108 shares of the Company’s common stock pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company has not filed a registration statement on Form S-8 to register the issuance of shares upon exercise of this inducement stock option. The inducement options grants have been issued outside of the 2015 Plan, but are subject to the terms and conditions of the 2015 Plan. As of September 30, 2022 , a total of 2,484,005 shares of common stock were reserved for issuance under the 2015 Plan, of which 439,867 shares of common stock are available for future grant. As of September 30, 2022 , a total of 7,813 and 2,044,138 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2021, a total of 8,240 and 1,345,955 options were outstanding under the 2006 and 2015 Plans, respectively. As of September 30, 2022 a total of 349,783 inducement options are outstanding. The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2021 1,422,195 $ 5.28 $ — Options granted 1,320,322 1.11 297.00 Options exercised — — Options forfeited ( 266,347 ) 2.29 Options expired ( 74,436 ) 6.04 Outstanding — Balance at September 30, 2022 2,401,734 $ 3.29 Vested and expected to vest — September 30, 2022 2,115,782 $ 3.55 Exercisable — September 30, 2022 873,633 $ 6.59 $ — Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by our Board of Directors for each of the respective periods. The intrinsic value of options exercised was $ 0 for both quarters ended September 30, 2022 and 2021. As of September 30, 2022 , there was $ 1.3 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.5 years. On December 14, 2021, Matt Plavan provided notice to the Company of his resignation as Arcadia’s president, chief executive officer and director, effective as of December 31, 2021. On December 19, 2021, Arcadia and Mr. Plavan entered into a Separation and Release Agreement (the “Separation Agreement”) which provided that the vesting of all unvested options previously issued to Mr. Plavan accelerated pursuant to the terms of the Separation Agreement. In addition, the Separation Agreement extended the post-termination exercise period of the accelerated options from 90 days to up to two and one-half years . The stock compensation expense related to the modification of Mr. Plavan’s stock options was $ 154,000 and it was recognized in selling, general and administrative expenses during the year ended December 31, 2021. In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected Term— The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards. Expected Volatility— The historical volatility data was computed using the daily closing prices for the Company’s shares during the equivalent period of the calculated expected term of the stock-based awards. Risk-Free Interest Rate— The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted. Expected Dividend— The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders. The fair value of stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected term (years) 5.69 6.08 6.41 6.34 Expected volatility 122 % 121 % 122 % 122 % Risk-free interest rate 2.99 % 0.97 % 2.59 % 0.83 % Dividend yield — — — — The Company recognized $ 314,000 and $ 897,000 of compensation expense for stock options awards for the three and nine months ended September 30, 2022, respectively. The Company recognized $ 354,000 and $ 1.0 million of compensation expense for stock options awards for the three and nine months ended September 30, 2021, respectively. Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15 % of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016 , the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of September 30, 2022 , the number of shares of common stock reserved for future issuance under the ESPP is 128,914 . The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2022 , 58,970 shares had been issued under the ESPP. The Company recorded $ 1,000 and $ 3,000 of ESPP related compensation expense for the three and nine months ended September 30, 2022 , respectively. The Company recorded $ 4,000 and $ 12,000 of ESPP related compensation expense for the three and nine months ended September 30, 2021 , respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes. The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21 %. The Company’s effective tax rate was 0.00 % for each of the three and nine months ended September 30, 2022 , and was - 0.04 % and - 0.02 % for the three and nine months ended September 30, 2021 . The difference between the effective tax rate and the federal statutory rate of 21 % was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets. The Company experienced an ownership change under IRC Section 382 as a result of the common shares issued in connection with the January 2021 Offering. This ownership change limited the Company’s ability to utilize its net operating loss carryforwards prior to expiration and certain net operating loss carryforwards were written off as a result. The Company is currently conducting additional analysis regarding the valuation of the Company at the time of the ownership change to assess what, if any, portion of the limitation may be reversed. Any adjustment to the amount of limitation will not impact the deferred tax asset balance due to the full valuation allowance. During the nine months ended September 30, 2022 , there were no material changes to the Company’s uncertain tax positions.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Leases The Company leases office and laboratory space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years , including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 10. Legal Matters From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings. Contingent Liability Related to the Anawah Acquisition In June 2005 , the Company completed its agreement and plan of merger and reorganization with Anawah, to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $ 5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $ 3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During the fourth quarter of 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of September 30, 2022 , the Company continues to pursue a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $ 2.0 million remains on the condensed consolidated balance sheet as an other noncurrent liability. Contingent Liability Related to the ISI Acquisition In August 2020, the Company acquired by merger ISI. A portion of the purchase price consideration for the acquisition in the amount of $ 280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The contingent consideration was measured and recorded at fair value. As a result of a remeasurement of the contingent consideration, we recorded a decrease to the related liability of $ 31,000 and $ 140,000 during the quarters ended March 31, 2022 and 2021, respectively. During the nine months ended September 30, 2022 , the remaining contingent liability of $ 39,000 was written-down to $ 0 as the probability of achievement of the 2022 revenue milestone is remote. Contracts The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2 % to 15 % of net revenue amounts as defined in the In-Licensing Agreements are or will be due. The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Share	16. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As the Company had net losses for the three and nine months ended September 30, 2022 and 2021, all potentially dilutive common shares were determined to be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Options to purchase common stock 2,401,734 1,554,909 2,401,734 1,554,909 Warrants to purchase common stock 11,350,011 11,510,011 11,350,011 11,510,011 Preferred investment options 4,958,631 — 4,958,631 — Total 18,710,376 13,064,920 18,710,376 13,064,920

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	17. Related-Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and the JSF share common officers and directors. JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $ 47,000 and $ 64,000 as of September 30, 2022 and December 31, 2021, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties. During the nine months ended September 30, 2021, the Company leased land on the island of Molokai, Hawaii from an entity owned by Kevin Comcowich, the Chair of the Company’s Board of Directors, and his wife. The Company used to grow hemp on this land to support the operations of its joint venture Archipelago Ventures Hawaii, until the expiration of the lease in February 2022. The original lease was executed in February 2019, covered 10 acres of land, had a term of two years and provided for rent payments of $ 1,200 per acre per year. In March and April 2020, the Company entered into two lease amendments for two additional 10 -acre parcels and two additional 15 -acre parcels , at the same lease rate of $ 1,200 per acre per year, and with a term of two years . The Company made lease payments in the amount of $ 0 and $ 81,000 during the nine months ended September 30, 2022 and 2021 , respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Management has evaluated subsequent events through November 10, 2022, the date that the financial statements were available to be issued.

Description of Business and B_2

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Organization	Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional office space in Dallas, TX, and additional facilities in American Falls, Idaho. The Company was reincorporated in Delaware in March 2015 . The Company is a producer and marketer of innovative, plant-based health and wellness products. Its history as a leader in science-based approaches to developing high-value crop improvements, as well as nutritionally enhanced food ingredients and health and wellness products, has laid the foundation for its path forward. The Company used advanced breeding techniques to develop these proprietary innovations which are now being commercialized through the sales of seed and grain, as well as food ingredients and products. The acquisition of the businesses of Lief Holdings, LLC (“Lief”), EKO Holdings, LLC (“Eko”) and Live Zola, LLC (“Zola”) added bath and body care products, as well as coconut water, to the Company’s portfolio. In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”, see Note 6), acquired the businesses of Eko, Lief, and Zola. The acquisition included consumer CBD brands like Soul Spring™, a CBD-infused botanical therapy brand in the natural category, Saavy Naturals™, a line of natural body care products and ProVault™, a CBD-infused sports performance formula made with natural ingredients, providing effective support and recovery for athletes. Also included in the purchase is Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. On July 8, 2022, the Company entered into an agreement to license Saavy Naturals™ to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). See Note 6 for a discussion of the licensing agreement. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 8) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $ 10.0 million on sales of Haab 4 soybeans (“HB4”) soybean. An additional $ 2.0 million in cash is to be paid upon achievement by Verdeca of reaching commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for “food and feed”. During the second quarter of 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $ 862,000 and a gain on sale of Verdeca of $ 1.1 million on the condensed consolidated statements of operations and comprehensive loss. As of September 30, 2022, the Company received payment of $ 500,000 with the remaining $ 1.5 million in accounts receivable and other receivables, which the Company anticipates to receive over the next six months pursuant to the agreement.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $ 10,000 and $ 152,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2022, respectively. Net loss attributable to non-controlling interest for the three and nine months ended September 30, 2021 was $ 661,000 and $ 1.2 million, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2022.
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of September 30, 2022, the Company had an accumulated deficit of $ 253.6 million, and cash and cash equivalents of $ 22.7 million . For the nine months ended September 30, 2022, the Company had a net loss of $ 11.3 million and net cash used in operations of $ 11.6 million. For the twelve months ended December 31, 2021, the Company had net losses of $ 16.1 million and net cash used in operations of $ 25.9 million. With cash and cash equivalents of $ 22.7 million as of September 30, 2022, the Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company does require additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs. Any of these actions could materially harm the business, results of operations and financial condition.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories, net consist of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 1,119 $ 1,851 Goods in process 92 842 Finished goods 3,115 4,234 Inventories $ 4,326 $ 6,927

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): September 30, 2022 December 31, 2021 Laboratory equipment $ 1,688 $ 2,659 Software and computer equipment 559 548 Machinery and equipment 653 1,809 Furniture and fixtures 108 211 Vehicles 333 417 Leasehold improvements 2,203 2,306 Property and equipment, gross 5,544 7,950 Less: accumulated depreciation and amortization ( 4,696 ) ( 5,659 ) Property and equipment, net $ 848 $ 2,291

Investments and Fair Value In_2

Investments and Fair Value Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Investments And Fair Value Instruments [Abstract]
Summary of Amortized Cost and Fair Value of Investment Securities Portfolio	The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2022 and December 31, 2021. (Dollars in thousands) Amortized Unrealized Unrealized Estimated September 30, 2022 Cash equivalents: Money market funds $ 20,477 $ — $ — $ 20,477 Total Assets at Fair Value $ 20,477 $ — $ — $ 20,477 (Dollars in thousands) Amortized Unrealized Unrealized Estimated December 31, 2021 Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842
Summary of Fair Value of Investment Securities	The fair value of the investment securities at September 30, 2022 were as follows: Fair Value Measurements at September 30, 2022 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 20,477 $ — $ — $ 20,477 Total Assets at Fair Value $ 20,477 $ — $ — $ 20,477 The fair value of the investment securities at December 31, 2021 were as follows: Fair Value Measurements at December 31, 2021 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 26,842 $ — $ — $ 26,842 Total Assets at Fair Value $ 26,842 $ — $ — $ 26,842
Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model	The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions at September 30, 2022: August 2022 Options August 2022 Placement Agent Options Remaining term (in years) 4.92 4.92 Expected volatility 128.5 % 128.5 % Risk-free interest rate 4.1 % 4.1 % Expected dividend yield 0 % 0 %
Summary of Changes in Fair Value and Other Adjustments of Liabilities	The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Dollars in thousands) Common Stock Common Common Common August 2022 August 2022 Contingent Total Balance as of December 31, 2021 $ 7 $ 170 $ 223 $ 2,993 $ — $ — $ 2,070 $ 5,463 Reclassification upon adoption ( 7 ) ( 170 ) ( 223 ) ( 2,993 ) — — — ( 3,392 ) Initial recognition — — — — 3,824 191 — 4,015 Change in fair value and other adjustments — — — — ( 1,791 ) ( 89 ) ( 70 ) ( 1,950 ) Balance as of September 30, 2022 $ — $ — $ — $ — $ 2,033 $ 102 $ 2,000 $ 4,135

Arcadia Wellness Acquisition (T

Arcadia Wellness Acquisition (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Schedule of Allocation Purchase Price of Assets Acquired at Fair Value at Acquisition Date	The following table presents the allocation of the purchase price of the assets acquired at fair value at the acquisition date: Purchase Price Inventory $ 840 Prepaid and other current assets 62 Fixed assets 308 Deposits 82 Customer list 360 Trade names and trademarks 2,900 Formulations 260 Goodwill 1,240 Total consideration allocated $ 6,052
Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations	The following unaudited pro-forma condensed consolidated results of operations for the three and nine months ended September 30, 2022 and 2021, have been prepared as if the acquisition of Arcadia Wellness had occurred on January 1, 2021 and includes adjustments for amortization of intangibles, and the addition to basic and diluted weighted average number of shares outstanding. For the Three Months For the Nine Months 2022 2021 2022 2021 Total revenues $ 1,878 $ 2,376 $ 8,956 $ 6,892 Net loss ( 2,877 ) ( 2,836 ) ( 11,284 ) ( 8,296 ) Net loss attributable to common stockholders $ ( 2,867 ) $ ( 2,175 ) $ ( 11,132 ) $ ( 7,109 ) Weighted average shares - Basic and diluted 24,552,543 22,175,423 22,984,816 21,286,380 Net loss per share attributable to common stockholders: Basic and diluted $ ( 0.12 ) $ ( 0.10 ) $ ( 0.48 ) $ ( 0.33 )

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	The Company’s intangible assets, net, consist of the following: September 30, 2022 December 31, 2021 Gross Accumulated Amortization Net Carrying Gross Accumulated Amortization Net Carrying Amortized intangible assets Intellectual property $ 254 $ 141 $ 113 $ 258 $ 107 $ 151 Customer lists 64 32 32 71 26 45 Total amortizable intangible assets $ 318 $ 173 $ 145 $ 329 $ 133 $ 196 Indefinite-lived intangible assets Brands and trademarks $ 228 $ — $ 228 $ 288 $ — $ 288 Total intangible asset, net $ 546 $ 173 $ 373 $ 617 $ 133 $ 484 (1) The gross carrying amounts included in this table reflect the effects of the impairments of intangible assets recorded during the year ended December 31, 2021, when the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of the acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $ 3.3 million in the condensed consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. (2) The Company recorded an impairment of intangible assets in the amount of $ 72,000 during the nine months ended September 30, 2022 related to the Radiance Beauty licensing agreement.
Schedule of Future Amortization of Intellectual Property and Customer Lists	As of September 30, 2022, future amortization of intellectual property and customer lists is as follows: Year Ending December 31, 2022 (excluding the nine months ended September 30, 2022) $ 13 2023 53 2024 53 2025 4 2026 4 Thereafter 18 Total $ 145

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Lessee Disclosure [Abstract]
Schedule of Leases	Leases consisted of the following (in thousands): Leases Classification September 30, 2022 December 31, 2021 Assets Operating lease assets Right of use asset $ 2,073 $ 3,081 Total leased assets $ 2,073 $ 3,081 Liabilities Current - Operating Operating lease liability- current $ 986 $ 1,074 Noncurrent - Operating Operating lease liability- noncurrent 1,269 2,220 Total leased liabilities $ 2,255 $ 3,294 Lease Cost Classification Three Three Nine Nine Operating lease cost SG&A and R&D Expenses $ 271 $ 319 $ 815 $ 955 Short term lease cost (1) R&D Expenses ( 7 ) 37 4 67 Short term lease cost SG&A Expenses — 14 0 29 Sublease income (2) SG&A and R&D Expenses ( 99 ) ( 10 ) ( 276 ) ( 43 ) Net lease cost $ 165 $ 360 $ 543 $ 1,008 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term September 30, 2022 December 31, 2021 Weighted-average remaining 2.3 2.7 Weighted-average discount rate 6.4 % 6.0 %

Warrants and Options (Tables)

Warrants and Options (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Issued to Purchase Common Stock	The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of September 30, 2022 or December 31, 2021, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at August 2022 Pre-Funded Warrants August 2022 perpetual $ 0.00 — — — 2,272,506 January 2021 Placement Agent Warrants January 2021 5.5 years $ 3.99 — 393,839 — 393,839 January 2021 Service and Performance Warrants (1) January 2021 2 years $ 3.08 — 7,500 — 7,500 December 2020 Warrants December 2020 5.5 years $ 3.00 — 2,618,658 — 2,618,658 December 2020 Placement Agent Warrants December 2020 5 years $ 3.82 — 130,933 — 130,933 July 2020 Warrants July 2020 5.5 years $ 3.85 — 641,416 — 641,416 July 2020 Placement Agent Warrants July 2020 5.5 years $ 4.97 — 32,071 — 32,071 May 2020 Warrants May 2020 5 years $ 4.78 — 1,392,345 — 1,392,345 May 2020 Placement Agent Warrants May 2020 5 years $ 6.13 — 69,617 — 69,617 March 2020 Service and Performance Warrants (1) March 2020 3 years $ 2.50 — 18,350 — 18,350 February 12, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 4.71 — 150,000 — — February 3, 2020 Service and Performance Warrants (1)(3) February 2020 2 years $ 4.91 — 10,000 — — September 2019 Placement Agent Warrants September 2019 5 years $ 9.48 — 65,942 — 65,942 June 2019 Placement Agent Warrants June 2019 5 years $ 6.29 — 74,479 — 74,479 April 2019 Service and Performance Warrants (1) April 2019 5 years $ 6.18 — 145,154 — 145,154 June 2018 Placement Agent Warrants June 2018 5 years $ 12.57 — 69,617 — 69,617 March 2018 Placement Agent Warrants March 2018 5 years $ 41.56 — 15,038 — 15,038 January 2021 Warrants (2) January 2021 5.5 years $ 3.13 — 3,938,392 — 3,938,392 September 2019 Warrants (2) September 2019 5.5 years $ 7.52 — 659,414 — 659,414 June 2019 Warrants (2) June 2019 5.5 years $ 5.00 — 435,830 — 435,830 June 2018 Warrants (2) June 2018 5.5 years $ 9.94 — — — — March 2018 Warrants (2) March 2018 5 years $ 10.73 — 641,416 — 641,416 Total — 11,510,011 — 13,622,517 (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and were adjusted to fair value at each balance sheet date. Upon adoption of ASU No. 2020-06 on January 1, 2022, all of the common stock warrant liabilities have been reclassified to equity classified common stock warrants, due to the elimination of the contingent cash payments as criteria for liability classification. (3) These warrants expired in February 2022 .
Summary of Key Terms and Activity of Liability Classified Preferred Investment Options	The key terms and activity of the liability classified preferred investment options are summarized as follows: Issuance Date Term Exercise Exercised Outstanding at Exercised Outstanding at August 2022 Options August 2022 5 years $ 0.93 — — — 4,722,506 August 2022 Placement Agent Options August 2022 5 years $ 1.32 — — — 236,125 Total — — — 4,958,631

Stock-Based Compensation and _2

Stock-Based Compensation and Employee Stock Purchase Program (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Activity Under Stock Incentive Plans	The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Weighted- Aggregate Outstanding — Balance at December 31, 2021 1,422,195 $ 5.28 $ — Options granted 1,320,322 1.11 297.00 Options exercised — — Options forfeited ( 266,347 ) 2.29 Options expired ( 74,436 ) 6.04 Outstanding — Balance at September 30, 2022 2,401,734 $ 3.29 Vested and expected to vest — September 30, 2022 2,115,782 $ 3.55 Exercisable — September 30, 2022 873,633 $ 6.59 $ —
Weighted-Average Fair Value Assumption of Stock Option Awards	The fair value of stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected term (years) 5.69 6.08 6.41 6.34 Expected volatility 122 % 121 % 122 % 122 % Risk-free interest rate 2.99 % 0.97 % 2.59 % 0.83 % Dividend yield — — — —

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2022 2021 2022 2021 Options to purchase common stock 2,401,734 1,554,909 2,401,734 1,554,909 Warrants to purchase common stock 11,350,011 11,510,011 11,350,011 11,510,011 Preferred investment options 4,958,631 — 4,958,631 — Total 18,710,376 13,064,920 18,710,376 13,064,920

Description of Business and B_3

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended						9 Months Ended		12 Months Ended
	Nov. 30, 2020	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Place of incorporation								Arizona
Year of incorporation								2002
Place of reincorporation								Delaware
Date of reincorporation								2015-03
Gain on sale of Verdeca		$ 0			$ 0			$ 1,138,000	$ 0
License revenue		1,878,000			2,376,000			8,956,000	4,609,000
Net loss attributable to non-controlling interest		(10,000)			(661,000)			(152,000)	(1,199,000)
Accumulated deficit		(253,615,000)						(253,615,000)		$ (226,485,000)
Cash and cash equivalents		22,719,000						22,719,000		28,685,000
Net loss		(2,877,000)	$ (3,797,000)	$ (4,610,000)	$ (2,836,000)	$ (5,422,000)	$ 1,681,000	(11,284,000)	(6,577,000)	(16,100,000)
Net cash used in operations								(11,621,000)	(19,208,000)	(25,900,000)
Payment received on accounts and other receivable								854,000	$ 0
Remaining accounts receivable and other receivables		2,726,000						2,726,000		$ 1,370,000
Verdeca LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gain on sale of Verdeca			1,100,000
Bioceres Crop Solutions [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue			$ 862,000
Bioceres Crop Solutions [Member] | Verdeca LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional cash receivable from sale of interest in joint venture	$ 2,000,000
Payment received on accounts and other receivable								500,000
Remaining accounts receivable and other receivables		$ 1,500,000						$ 1,500,000
Bioceres Crop Solutions [Member] | Verdeca LLC [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash shares and royalty receivable	$ 10,000,000

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 01, 2022	Sep. 30, 2022	Dec. 31, 2021
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accumulated deficit		$ (253,615)	$ (226,485)
Additional paid-in capital		$ 278,618	$ 257,515
Accounting Standards Update 2020-06 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accumulated deficit	$ 16,000
Additional paid-in capital	19,400
Decrease in common stock warrant liabilities	$ 3,400
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Accounting Standards Update 2021-04 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Inventory [Line Items]
Write-down of inventory	$ 15,000	$ 818,000	$ 1,530,000	$ 1,802,000
Radiance Beauty Licensing Agreement [Member]
Inventory [Line Items]
Write-down of inventory			$ 394,000

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 1,119	$ 1,851
Goods in process	92	842
Finished goods	3,115	4,234
Inventories	$ 4,326	$ 6,927

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 5,544	$ 7,950
Less accumulated depreciation and amortization	(4,696)	(5,659)
Property and equipment, net	848	2,291
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,688	2,659
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	559	548
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	653	1,809
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	108	211
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	333	417
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,203	$ 2,306

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Depreciation expense			$ 354,000	$ 737,000
Property and equipment, gross	$ 5,544,000		5,544,000		$ 7,950,000
Impairment of property and equipment	24,000	$ 1,108,000	370,000	1,319,000
Gain on sale of property and equipment	0		386,000
Proceeds from sale of property and equipment	5,000		897,000	2,000
Assets held for sale		0		0
Property and equipment classified as assets held for sale, fair value	254,000		254,000
Radiance Beauty Licensing Agreement [Member]
Property Plant And Equipment [Line Items]
Impairment of property and equipment			320,000
Archipelago Ventures Hawaii, LLC [Member]
Property Plant And Equipment [Line Items]
Impairment of property and equipment		$ 1,100,000		$ 1,300,000
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 10,000		$ 10,000		$ 267,000

Investments and Fair Value In_3

Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 20,477	$ 26,842
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	20,477	26,842
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	20,477	26,842
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	$ 20,477	$ 26,842

Investments and Fair Value In_4

Investments and Fair Value Instruments - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0
Impairment charges	$ 442,000	$ 1,400,000

Investments and Fair Value In_5

Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets at Fair Value
Total Assets at Fair Value	$ 20,477	$ 26,842
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	20,477	26,842
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	20,477	26,842
Level 1 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	20,477	26,842
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 2 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	$ 0	$ 0

Investments and Fair Value In_6

Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Level 3 [Member]	Sep. 30, 2022
Remaining Term [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	4 years 11 months 1 day
Remaining Term [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	4 years 11 months 1 day
Expected Volatility [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	128.5
Expected Volatility [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	128.5
Risk-Free Interest Rate [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	4.1
Risk-Free Interest Rate [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	4.1
Expected Dividend Yield [Member] | August 2022 Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0
Expected Dividend Yield [Member] | August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0

Investments and Fair Value In_7

Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Liabilities (Detail) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 5,463
Initial recognition	4,015
Change in fair value and other adjustments	(1,950)
Ending Balance	4,135
Common Stock Warrant Liability [Member] | March 2018 Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	7
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
Common Stock Warrant Liability [Member] | June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	170
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
Common Stock Warrant Liability [Member] | September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	223
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
Common Stock Warrant Liability [Member] | January 2021 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,993
Initial recognition	0
Change in fair value and other adjustments	0
Ending Balance	0
August 2022 Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	3,824
Change in fair value and other adjustments	(1,791)
Ending Balance	2,033
August 2022 Placement Agent Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	191
Change in fair value and other adjustments	(89)
Ending Balance	102
Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,070
Initial recognition	0
Change in fair value and other adjustments	(70)
Ending Balance	2,000
ASU 2020-06 [Member] | Reclassification upon Adoption [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(3,392)
ASU 2020-06 [Member] | Reclassification upon Adoption [Member] | Common Stock Warrant Liability [Member] | March 2018 Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(7)
ASU 2020-06 [Member] | Reclassification upon Adoption [Member] | Common Stock Warrant Liability [Member] | June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(170)
ASU 2020-06 [Member] | Reclassification upon Adoption [Member] | Common Stock Warrant Liability [Member] | September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(223)
ASU 2020-06 [Member] | Reclassification upon Adoption [Member] | Common Stock Warrant Liability [Member] | January 2021 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	(2,993)
ASU 2020-06 [Member] | Reclassification upon Adoption [Member] | August 2022 Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	0
ASU 2020-06 [Member] | Reclassification upon Adoption [Member] | August 2022 Placement Agent Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	0
ASU 2020-06 [Member] | Reclassification upon Adoption [Member] | Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Ending Balance	$ 0

Arcadia Wellness Acquisition -

Arcadia Wellness Acquisition - Additional Information (Detail) - USD ($)		3 Months Ended		7 Months Ended	9 Months Ended		12 Months Ended
	May 17, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Lease option to extend, description					Some leases (the Davis and Dallas offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Total revenues		$ 1,878,000	$ 2,376,000		$ 8,956,000	$ 4,609,000
Net loss attributable to common stockholders		2,867,000	2,175,000		11,132,000	5,378,000
Inventories written down		15,000	818,000		1,530,000	1,802,000
Impairment of property and equipment					370,000	1,319,000
Impairment of intangible asset		0	$ 120,000		$ 72,000	120,000	$ 3,300,000
Radiance Beauty Licensing Agreement [Member]
Business Acquisition [Line Items]
Effective rate of royalty of gross sales					4%
Accounts receivable written-down					$ 21,000
Inventories written down					394,000
Impairment of property and equipment					320,000
Impairment of intangible asset					72,000
Accrued salaries		355,000			355,000
Accrued rent, maintenance and utilities		$ 19,000			19,000
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Purchase price consideration	$ 6,100,000
Cash paid for Acquisition	4,000,000
Business combination, equity interest issuable, value	$ 2,100,000
Operating leases, term of contract	3 years
Total revenues				$ 4,300,000	5,600,000
Net loss attributable to common stockholders				$ 7,500,000	$ (1,300,000)
Intangible assets, net	$ 3,500,000
Weighted average useful life	12 years 10 months 24 days
Goodwill	$ 1,240,000
Arcadia Wellness [Member] | Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets, net	2,900,000
Arcadia Wellness [Member] | Customer List [Member]
Business Acquisition [Line Items]
Intangible assets, net	$ 360,000
Useful life	15 years
Arcadia Wellness [Member] | Formulations [Member]
Business Acquisition [Line Items]
Intangible assets, net	$ 260,000
Useful life	10 years
Arcadia Wellness [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs						$ 850,000
Common Stock [Member] | Arcadia Wellness [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares	827,401

Arcadia Wellness Acquisition _2

Arcadia Wellness Acquisition - Schedule of Allocation Purchase Price of Assets Acquired at Fair Value at Acquisition Date (Detail) - Arcadia Wellness [Member] $ in Thousands	May 17, 2021 USD ($)
Business Acquisition [Line Items]
Inventory	$ 840
Prepaid and other current assets	62
Fixed assets	308
Deposits	82
Customer list	360
Trade names and trademarks	2,900
Formulations	260
Goodwill	1,240
Total consideration allocated	$ 6,052

Arcadia Wellness Acquisition _3

Arcadia Wellness Acquisition - Schedule of Unaudited Pro-forma Condensed Consolidated Results of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Acquisition [Line Items]
Weighted average shares - Basic	24,552,543	22,177,423	22,984,816	20,976,105
Weighted average shares - Diluted	24,552,543	22,177,423	22,984,816	20,976,105
Arcadia Wellness [Member]
Business Acquisition [Line Items]
Total revenues	$ 1,878	$ 2,376	$ 8,956	$ 6,892
Net loss	(2,877)	(2,836)	(11,284)	(8,296)
Net loss attributable to common stockholders	$ (2,867)	$ (2,175)	$ (11,132)	$ (7,109)
Weighted average shares - Basic	24,552,543	22,175,423	22,984,816	21,286,380
Weighted average shares - Diluted	24,552,543	22,175,423	22,984,816	21,286,380
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.12)	$ (0.10)	$ (0.48)	$ (0.33)

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2022		Dec. 31, 2021
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	$ 318	[1]	$ 329	[2]
Amortized intangible assets, Accumulated Amortization	173		133
Finite-Lived Intangible Assets, Net, Total	145		196
Total intangible asset, Gross Carrying Amount	546	[1]	617	[2]
Total intangible asset, Net Carrying Amount	373		484
Brands and Trademarks [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, Gross Carrying Amount	228	[1]	288	[2]
Indefinite-lived intangible assets, Net Carrying Amount	228		288
Intellectual Property [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	254	[1]	258	[2]
Amortized intangible assets, Accumulated Amortization	141		107
Finite-Lived Intangible Assets, Net, Total	113		151
Customer Lists [Member]
Finite And Indefinite Lived Intangible Assets [Line Items]
Amortized intangible assets, Gross Carrying Amount	64	[1]	71	[2]
Amortized intangible assets, Accumulated Amortization	32		26
Finite-Lived Intangible Assets, Net, Total	$ 32		$ 45
[1] The Company recorded an impairment of intangible assets in the amount of $ 72,000 during the nine months ended September 30, 2022 related to the Radiance Beauty licensing agreement. The gross carrying amounts included in this table reflect the effects of the impairments of intangible assets recorded during the year ended December 31, 2021, when the Company estimated an overall decrease in the sales forecast for AW products, due to an inventory item rationalization, in addition to a decrease in the sales forecast of ISI seeds, related to the saturated hemp seed market. As a result, Arcadia performed a quantitative intangible assets impairment test. The Company used a discounted cash flow approach to develop the fair value of the acquired intellectual property, customer lists, brands and trademarks. As a result of this assessment, Arcadia recorded an impairment of intangible assets in the amount of $ 3.3 million in the condensed consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Intangible Assets, Net (Parenthetical) (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible asset	$ 0	$ 120,000	$ 72,000	$ 120,000	$ 3,300,000
Radiance Beauty Licensing Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible asset			$ 72,000

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Detail) - Intellectual Property and Customer Lists [Member]	9 Months Ended
	Sep. 30, 2022
Minimum [Member]
Finite Lived Intangible Assets [Line Items]
Useful life of intangible assets amortized	4 years
Maximum [Member]
Finite Lived Intangible Assets [Line Items]
Useful life of intangible assets amortized	15 years

Intangible Assets, Net - Sche_3

Intangible Assets, Net - Schedule of Future Amortization of Intellectual Property and Customer Lists (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
2022 (excluding the nine months ended September 30, 2022)	$ 13
2023	53
2024	53
2025	4
2026	4
Thereafter	18
Finite-Lived Intangible Assets, Net, Total	$ 145	$ 196

Consolidated Joint Venture - Ad

Consolidated Joint Venture - Additional Information (Detail)		3 Months Ended		9 Months Ended
	Aug. 09, 2019 Individual	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Schedule Of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest		$ 10,000	$ 661,000	$ 152,000	$ 1,199,000
Archipelago Ventures Hawaii, LLC [Member] | Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		50.75%		50.75%
Capital contributions		$ 3,100,000		$ 3,100,000
Archipelago Ventures Hawaii, LLC [Member] | Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		49.25%		49.25%
Capital contributions		$ 3,000,000		$ 3,000,000

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Leases - Additional Information

Leases - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2022 USD ($)
Lessee Lease Description [Line Items]
Operating lease term, expiration	2024-05
Early termination fees	$ 47,000
Existence of option to extend	true
Lease option to extend, description	Some leases (the Davis and Dallas offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Assets
Operating lease assets	$ 2,073		$ 2,073		$ 3,081
Total leased assets	2,073		2,073		3,081
Liabilities
Current - Operating	986		986		1,074
Noncurrent - Operating	1,269		1,269		2,220
Total leased liabilities	2,255		2,255		$ 3,294
Lease Cost
Net lease cost	$ 165	$ 360	$ 543	$ 1,008
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	2 years 3 months 18 days		2 years 3 months 18 days		2 years 8 months 12 days
Weighted-average discount rate	6.40%		6.40%		6%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 271	319	$ 815	955
Sublease income	(99)	(10)	(276)	(43)
R&D Expenses [Member]
Lease Cost
Short term lease cost	7	37	4	67
SG&A Expenses [Member]
Lease Cost
Short term lease cost	$ 0	$ 14	$ 0	$ 29

Equity Financing - Additional I

Equity Financing - Additional Information (Detail)

1 Months Ended

3 Months Ended

9 Months Ended

Aug. 16, 2022 USD ($) $ / shares

Aug. 31, 2022 USD ($) $ / shares shares

Jan. 31, 2021 USD ($) $ / shares shares

Dec. 31, 2020 USD ($) $ / shares shares

Sep. 30, 2019 USD ($) $ / shares shares

Jun. 30, 2019 USD ($) $ / shares shares

Jun. 30, 2018 USD ($) $ / shares shares

Mar. 31, 2018 USD ($) $ / shares shares

Sep. 30, 2022 USD ($) $ / shares

Sep. 30, 2021 USD ($)

Sep. 30, 2022 USD ($) $ / shares

Sep. 30, 2021 USD ($)

Dec. 31, 2021 $ / shares

Jan. 28, 2021

Class Of Warrant Or Right [Line Items]

Common stock, par value | $ / shares

$ 0.001

$ 0.001

$ 0.001

Offering costs allocated to common stock warrant liability and expensed | $

$ 314,000

$ 0

$ 314,000

$ 769,000

Maximum [Member]

Class Of Warrant Or Right [Line Items]

Proceeds from issuance, aggregate offering prices | $

$ 50,000,000

March 2018 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

1,201,634

Warrant issued, shares of common stock called by warrant

1,282,832

Warrants issued, exercise price | $ / shares

$ 10.7258

August 2022 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

2,450,000

Offering closing period

Aug. 16, 2022

August 2022 Purchase Agreement [Member] | Pre Funded Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

2,272,506

Warrants issued, exercise price | $ / shares

$ 0.0001

August 2022 Purchase Agreement [Member] | Preferred Investment Options [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

4,722,506

Exercise price | $ / shares

$ 0.93376

Proceeds from issuance of common stock pre-funded warrants and preferred investment options | $

$ 5,000,000

Warrants expiration period

5 years

December 2020 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

2,618,658

Proceeds from issuance of common stock and warrants gross | $

$ 8,000,000

Offering closing period

Dec. 22, 2020

December 2020 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

2,618,658

Warrants issued, exercise price | $ / shares

$ 3

Warrants expiration period

5 years 6 months

September 2019 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

1,318,828

Proceeds from issuance of common stock and warrants gross | $

$ 10,000,000

Offering closing period

Sep. 05, 2019

September 2019 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

659,414

Warrants issued, exercise price | $ / shares

$ 7.52

Warrants expiration period

5 years 6 months

June 2019 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

1,489,575

Proceeds from issuance of common stock and warrants gross | $

$ 7,500,000

Offering closing period

Jun. 14, 2019

June 2019 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

1,489,575

Warrants issued, exercise price | $ / shares

$ 5

Warrants expiration period

5 years 6 months

June 2018 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

1,392,345

Proceeds from issuance of common stock and warrants gross | $

$ 14,000,000

Offering closing period

Jun. 14, 2018

June 2018 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

1,392,345

Warrants issued, exercise price | $ / shares

$ 9.94

Warrants expiration period

5 years 6 months

June 2018 Placement Agent Warrants [Member] | June 2018 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

69,617

Warrants issued, exercise price | $ / shares

$ 12.568

Warrant, exercisable term

5 years

June 2019 Placement Agent Warrants [Member] | June 2019 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

74,479

Warrants issued, exercise price | $ / shares

$ 6.2938

Warrant, exercisable term

5 years

September 2019 Placement Agent Warrants [Member] | September 2019 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

65,942

Warrants issued, exercise price | $ / shares

$ 9.4781

Warrant, exercisable term

5 years

August 2022 Options and August 2022 Placement Agent Options [Member]

Class Of Warrant Or Right [Line Items]

Expected volatility

128.46%

Stock price | $ / shares

$ 0.94

Risk-free interest rate

2.97%

Expected term

5 years

August 2022 Placement Agent Options [Member]

Class Of Warrant Or Right [Line Items]

Fair value assumptions, value | $

$ 191,000

Offering costs | $

488,000

Allocation of common stock option liability expense | $

314,000

Remaining offering costs allocated to common stock and offset to additional paid in capital | $

365,000

August 2022 Placement Agent Options [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Offering costs | $

$ 679,000

August 2022 Placement Agent Options [Member] | August 2022 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

236,125

Warrants issued, exercise price | $ / shares

$ 1.32

Warrant, exercisable term

5 years

December 2020 Placement Agent Warrants [Member] | December 2020 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

130,933

Warrants issued, exercise price | $ / shares

$ 3.8188

Warrant, exercisable term

5 years

January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

7,876,784

Warrant issued, shares of common stock called by warrant

3,938,392

Warrants issued, exercise price | $ / shares

$ 3.13

Proceeds from issuance of common stock and warrants gross | $

$ 25,100,000

Warrants expiration period

5 years 6 months

Remaining offering costs allocated to common stock and offset to additional paid in capital | $

$ 2,000,000

January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Offering costs allocated to common stock warrant liability and expensed | $

$ 769,000

January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Expected Volatility [Member]

Class Of Warrant Or Right [Line Items]

Preferred investment options liability, measurement input

1.238

January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Stock Price [Member]

Class Of Warrant Or Right [Line Items]

Preferred investment options liability, measurement input

2.88

January 2021 Private Placement [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member] | Risk-Free Interest Rate [Member]

Class Of Warrant Or Right [Line Items]

Preferred investment options liability, measurement input

0.5

January 2021 Private Placement [Member] | January 2021 Placement Agent Warrants [Member] | January 2021 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

393,839

Warrants issued, exercise price | $ / shares

$ 3.99

Offering costs | $

$ 1,900,000

Warrant, exercisable term

5 years 6 months

Issuance of placement agent warrants | $

$ 942,000

January 2021 Private Placement [Member] | January 2021 Placement Agent Warrants [Member] | January 2021 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Offering costs | $

$ 2,800,000

March 2018 Private Placement [Member] | March 2018 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued

300,752

Warrant issued, shares of common stock called by warrant

300,752

Warrants issued, exercise price | $ / shares

$ 45.75

Proceeds from issuance of common stock and warrants gross | $

$ 10,000,000

Warrants expiration period

5 years

March 2018 Private Placement [Member] | March 2018 Placement Agent Warrants [Member] | March 2018 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant

15,038

Warrants issued, exercise price | $ / shares

$ 41.5625

Warrant, exercisable term

5 years

Warrants and Options - Summary

Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Exercised during the Year	0	0
Outstanding	13,622,517	11,510,011
August 2022 Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-08
Term	perpetual
Exercise Price Per Share	$ 0
Exercised during the Year	0	0
Outstanding	2,272,506	0
January 2021 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 3.99
Exercised during the Year	0	0
Outstanding	393,839	393,839
January 2021 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	2 years
Exercise Price Per Share	$ 3.08
Exercised during the Year	0	0
Outstanding	7,500	7,500
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 3
Exercised during the Year	0	0
Outstanding	2,618,658	2,618,658
December 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years
Exercise Price Per Share	$ 3.82
Exercised during the Year	0	0
Outstanding	130,933	130,933
July 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 3.85
Exercised during the Year	0	0
Outstanding	641,416	641,416
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 4.97
Exercised during the Year	0	0
Outstanding	32,071	32,071
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 4.78
Exercised during the Year	0	0
Outstanding	1,392,345	1,392,345
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 6.13
Exercised during the Year	0	0
Outstanding	69,617	69,617
March 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-03
Term	3 years
Exercise Price Per Share	$ 2.50
Exercised during the Year	0	0
Outstanding	18,350	18,350
February 12, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.71
Exercised during the Year	0	0
Outstanding	0	150,000
February 3, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.91
Exercised during the Year	0	0
Outstanding	0	10,000
September 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years
Exercise Price Per Share	$ 9.48
Exercised during the Year	0	0
Outstanding	65,942	65,942
June 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years
Exercise Price Per Share	$ 6.29
Exercised during the Year	0	0
Outstanding	74,479	74,479
April 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-04
Term	5 years
Exercise Price Per Share	$ 6.18
Exercised during the Year	0	0
Outstanding	145,154	145,154
June 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years
Exercise Price Per Share	$ 12.57
Exercised during the Year	0	0
Outstanding	69,617	69,617
March 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 41.56
Exercised during the Year	0	0
Outstanding	15,038	15,038
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 3.13
Exercised during the Year	0	0
Outstanding	3,938,392	3,938,392
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 7.52
Exercised during the Year	0	0
Outstanding	659,414	659,414
June 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years 6 months
Exercise Price Per Share	$ 5
Exercised during the Year	0	0
Outstanding	435,830	435,830
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years 6 months
Exercise Price Per Share	$ 9.94
Exercised during the Year	0	0
Outstanding	0	0
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 10.73
Exercised during the Year	0	0
Outstanding	641,416	641,416

Warrants and Options - Summar_2

Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2022
February 12, 2020 Service and Performance Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant expiration month and year	2022-02
February 3, 2020 Service and Performance Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant expiration month and year	2022-02

Warrants and Options - Summar_3

Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
August 2022 Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise price Per Share	$ 0.93
Exercised	0	0
Outstanding	4,722,506	0
August 2022 Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise price Per Share	$ 1.32
Exercised	0	0
Outstanding	236,125	0
August 2022 Options and Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercised	0	0
Outstanding	4,958,631	0

Stock-Based Compensation and _3

Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Feb. 02, 2022 shares

Dec. 19, 2021

Dec. 14, 2021

May 17, 2021 shares

May 20, 2015 shares

May 14, 2015

Jun. 30, 2019 shares

Sep. 30, 2022 USD ($) shares

Sep. 30, 2021 USD ($)

Sep. 30, 2022 USD ($) IncentivePlan shares

Sep. 30, 2021 USD ($)

Dec. 31, 2021 USD ($) shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of equity incentive plans | IncentivePlan

2

Shares Subject to Outstanding, Options granted

1,320,322

Total number of options outstanding

2,401,734

2,401,734

1,422,195

Intrinsic value of options exercised | $

$ 0

$ 0

Unrecognized compensation cost related to unvested stock-based compensation grants | $

$ 1,300,000

$ 1,300,000

Weighted-average remaining recognition period

2 years 6 months

Stock-based compensation | $

$ 314,000

$ 354,000

$ 897,000

1,035,000

2015 Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total number of shares reserved for issuance under plan

128,914

128,914

Stock-based compensation | $

$ 1,000

$ 4,000

$ 3,000

$ 12,000

Percentage in payroll deductions to acquire shares of common stock

15%

Purchase plan offering period

6 months

Employees are able to purchase company's common stock on first trading day of offering period, percentage

85%

Issuance of common stock pursuant to employee stock purchase plan

58,970

First offering period, start date

May 14, 2015

First offering period, end date

Feb. 01, 2016

Inducement Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares Subject to Outstanding, Options granted

248,000

Total number of options outstanding

349,783

349,783

Inducement Stock Option [Member] | Stanley Jacot, Jr. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares Subject to Outstanding, Options granted

316,108

Separation Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options exercisable period

2 years 6 months

90 days

Separation Agreement [Member] | Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation | $

$ 154,000

2015 Omnibus Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Terms under the plan

The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.

Total number of shares reserved for issuance under plan

154,387

2,484,005

2,484,005

Options vesting period

4 years

Additional shares authorized for issuance under the plan

120,000

Common stock available for future grant

439,867

439,867

Total number of options outstanding

2,044,138

2,044,138

1,345,955

2015 Omnibus Equity Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options exercisable period

10 years

2006 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total number of shares reserved for issuance under plan

10,637

Total number of options outstanding

7,813

7,813

8,240

Stock-Based Compensation and _4

Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Shares Subject to Outstanding, Beginning Balance | shares	1,422,195
Shares Subject to Outstanding, Options granted | shares	1,320,322
Shares Subject to Outstanding, Options exercised | shares	0
Shares Subject to Outstanding, Options Forfeited | shares	(266,347)
Shares Subject to Outstanding, Options Expired | shares	(74,436)
Shares Subject to Outstanding, Ending Balance | shares	2,401,734
Shares Subject to Outstanding, Vested and expected to vest | shares	2,115,782
Shares Subject to Outstanding, Exercisable | shares	873,633
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance | $ / shares	$ 5.28
Weighted-Average Exercise Price Per Share, Options granted | $ / shares	1.11
Weighted-Average Exercise Price Per Share, Options exercised | $ / shares	0
Weighted-Average Exercise Price Per Share, Options forfeited | $ / shares	2.29
Weighted-Average Exercise Price Per Share, Options expired | $ / shares	6.04
Weighted Average Exercise Price Per Share, Outstanding Ending Balance | $ / shares	3.29
Weighted Average Exercise Price Per Share, Vested and expected to vest | $ / shares	3.55
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 6.59
Aggregate Intrinsic Value, Beginning Balance | $	$ 0
Aggregate Intrinsic Value, Options Granted | $	297,000
Aggregate Intrinsic Value, Ending Balance | $	$ 0

Stock-Based Compensation and _5

Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 8 months 8 days	6 years 29 days	6 years 4 months 28 days	6 years 4 months 2 days
Expected volatility	122%	121%	122%	122%
Risk-free interest rate	2.99%	0.97%	2.59%	0.83%
Dividend yield	0%	0%	0%	0%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Federal statutory tax rate			21%
Effective tax rate	0%	(0.04%)	0%	(0.02%)
Uncertain tax positions	$ 0		$ 0

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Aug. 31, 2020 USD ($) Installment shares	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2010 USD ($) Installment Program	Dec. 31, 2021 USD ($)	Jun. 30, 2005 USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,000,000				$ 2,000,000			$ 2,070,000
Change in fair value of contingent consideration		0		$ 0		$ (70,000)	$ (140,000)
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability								$ 3,000,000		$ 5,000,000
Date of merger and reorganization						Jun. 30, 2005
Restructuring activities, description						As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased | Installment								3
Number of development programs | Program								6
Other noncurrent liability		$ 2,000,000				$ 2,000,000
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years				3 years
Remaining amount paid in multiple installments	$ 280,000
Change in fair value of contingent consideration			$ (31,000)		$ (140,000)
Remaining contingent liability		$ 39,000				$ 39,000
Business combination remaining contingent liability written-down						$ 0
Industrial Seed Innovations [Member] | Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable | Installment	2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year				1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements						2%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years				5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements						15%
Maximum [Member] | Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	132,626

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	18,710,376	13,064,920	18,710,376	13,064,920
Option to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	2,401,734	1,554,909	2,401,734	1,554,909
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	11,350,011	11,510,011	11,350,011	11,510,011
Preferred Investment Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	4,958,631	0	4,958,631	0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail)	1 Months Ended			9 Months Ended
	Apr. 30, 2020 USD ($) a Lease	Mar. 31, 2020 USD ($) a	Feb. 28, 2019 USD ($) a	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Related Party Transaction [Line Items]
Royalty fees due				$ 47,000		$ 64,000
Number of lease amendments | Lease	2
Lease payments				0	$ 81,000,000
Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land | a			10
Operating leases, term of contract			2 years
Rent payments			$ 1,200
Mr. Kevin Comcowich [Member] | Amendment [Member]
Related Party Transaction [Line Items]
Acres of land | a	15	10
Operating leases, term of contract	2 years	2 years
Number of additional properties under lease agreement	two additional 15-acre parcels	two additional 10-acre parcels
Rent payments	$ 1,200	$ 1,200
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due				$ 47,000		$ 64,000